Display options
Cite
André M, Vander Borght T, Bosly A. Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats. Adv Hematol. 2010;2011:430679doi: 10.1155/2011/430679.
André, M., Vander Borght, T., & Bosly, A. (2011). Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats. Advances in hematology, 2011430679. https://doi.org/10.1155/2011/430679
André, M, et al. "Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats." Advances in hematology vol. 2011 (2011): 430679. doi: https://doi.org/10.1155/2011/430679
André M, Vander Borght T, Bosly A. Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats. Adv Hematol. 2011;2011:430679. doi: 10.1155/2011/430679. Epub 2010 Dec 27. PMID: 21234093; PMCID: PMC3017950.
Copy Download .nbib Format: NLM
Share it on

Adv Hematol. 2011;2011:430679. doi: 10.1155/2011/430679. Epub 2010 Dec 27.

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats.

Advances in hematology

M André, T Vander Borght, A Bosly

Affiliations

  1. Department of Hematology, Grand Hôpital de Charleroi, Grand Rue, 3, 6000 Charleroi, Belgium.

PMID: 21234093 PMCID: PMC3017950 DOI: 10.1155/2011/430679

Abstract

FDG-PET has recently emerged as an important tool for the management of Hodgkins lymphoma. Although its use for initial staging and response evaluation at the end of treatment is well established, the place of interim PET for response assessment and subsequent treatment tailoring is still quite controversial. The use of interim PET after a few cycles of chemotherapy may allow treatment reduction for good responders, leading to lesser treatment toxicities as well as early treatment adaptation for bad responders with a potential higher chance for cure. Interpretation of interim PET is a rapidly moving field. Actually, visual interpretation is preferred over quantitative interpretation in this situation. The notion of minimal residual uptake emerged for faint persisting FDG uptake, but has evolved during the recent years. Guidelines using mediastinum and liver as references have been proposed at the expert meeting in Deauville 2009. Actually, several trials are ongoing both for localised and advanced disease to evaluate the FDG-PET potential for early treatment monitoring and tailoring. Until the results of these prospective randomized trials become available, treatment changes according to the interim PET results should remain inappropriate and limited to well-conducted clinical trials.

References

  1. J Clin Oncol. 2010 Sep 20;28(27):4199-206 - PubMed
  2. Haematologica. 2010 Jul;95(7):1198-206 - PubMed
  3. Leuk Lymphoma. 2009 Aug;50(8):1257-60 - PubMed
  4. N Engl J Med. 2010 Aug 12;363(7):640-52 - PubMed
  5. J Clin Oncol. 2007 Aug 20;25(24):3746-52 - PubMed
  6. J Nucl Med. 2007 Oct;48(10):1626-32 - PubMed
  7. Ann Oncol. 2008 Oct;19(10):1770-3 - PubMed
  8. Cancer. 2009 Apr 15;115(8):1680-91 - PubMed
  9. Ann Oncol. 2010 Jan;21(1):126-32 - PubMed
  10. Mol Imaging Biol. 2004 Nov-Dec;6(6):411-6 - PubMed
  11. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):823-8 - PubMed
  12. Cancer. 2006 Dec 1;107(11):2678-87 - PubMed
  13. Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):181-200 - PubMed
  14. Eur Radiol. 2008 Jun;18(6):1114-22 - PubMed
  15. J Clin Oncol. 2005 Jul 20;23(21):4634-42 - PubMed
  16. Nucl Med Commun. 2007 Oct;28(10):798-803 - PubMed
  17. J Clin Oncol. 2009 Sep 20;27(27):4548-54 - PubMed
  18. Eur J Haematol. 2007 Mar;78(3):206-12 - PubMed
  19. Haematologica. 2006 Apr;91(4):475-81 - PubMed
  20. Blood. 2006 Jan 1;107(1):52-9 - PubMed
  21. Ann Oncol. 2005 Jul;16(7):1160-8 - PubMed
  22. J Clin Oncol. 2009 Apr 10;27(11):1906-14 - PubMed
  23. J Nucl Med. 2006 Jun;47(6):1059-66 - PubMed
  24. Ann Oncol. 2009 Nov;20(11):1848-53 - PubMed
  25. Semin Radiat Oncol. 2007 Jul;17(3):190-7 - PubMed
  26. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1824-33 - PubMed
  27. J Clin Oncol. 2009 Feb 10;27(5):805-11 - PubMed
  28. J Clin Oncol. 2009 Jun 1;27(16):2739-41 - PubMed
  29. Blood. 2007 Nov 15;110(10):3507-16 - PubMed
  30. N Engl J Med. 2007 Nov 8;357(19):1916-27 - PubMed
  31. Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2320-33 - PubMed
  32. Radiology. 2004 Sep;232(3):823-9 - PubMed
  33. J Clin Oncol. 2007 Feb 10;25(5):571-8 - PubMed
  34. Blood. 2004 Dec 1;104(12):3483-9 - PubMed

Publication Types